Tandem Wealth Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,568 shares of the company’s stock, valued at approximately $630,000. Johnson & Johnson comprises about 0.4% of Tandem Wealth Advisors LLC’s holdings, making the stock its 22nd largest holding.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Veracity Capital LLC increased its stake in shares of Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after buying an additional 59 shares during the last quarter. Sandy Cove Advisors LLC increased its stake in Johnson & Johnson by 1.6% during the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after purchasing an additional 60 shares during the last quarter. LCM Capital Management Inc increased its stake in Johnson & Johnson by 0.7% during the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC increased its stake in Johnson & Johnson by 2.3% during the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Finally, Sierra Capital LLC increased its stake in Johnson & Johnson by 0.6% during the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Stock Performance
JNJ stock opened at $164.23 on Friday. The company has a market capitalization of $426.79 billion, a P/E ratio of 34.36, a PEG ratio of 2.76 and a beta of 0.54. The company has a 50-day simple moving average of $160.73 and a 200 day simple moving average of $164.06. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 2.90%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 99.58%.
Analyst Upgrades and Downgrades
Several analysts have weighed in on JNJ shares. Atlantic Securities lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Raymond James reduced their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Finally, Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.57.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Micron Building Goodwill In Asia, Near $2 Billion Investment
- Is Twilio On The Verge Of A Comeback?
- Broadcom: All-Time Highs But Still Good Value
- Leverage AI And Build A Fortress Portfolio With Adobe
- 2 Small-Caps With Large-Cap Potential
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
